In Reply

Rainer Porschen(Klinikum Bremen-Mitte), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Stefan Kubicka(Medizinische Hochschule Hannover), Axel Grothey(Campbell Clinic), Werner Freier(Mayo Clinic in Florida), Thomas Seufferlein(Universität Ulm), Ullrich Graeven(Kliniken Maria Hilf), Axel Hinke, Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Albrecht Kretzschmar(Roche (Switzerland)), Richard Greil(Paracelsus Medical University)

Journal of Clinical Oncology

October 30, 2007

10.1200/jco.2007.13.4841

Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

|Nature|2011|1.6k

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

|New England Journal of Medicine|2019|1.5k